Cyclerion Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT03795519
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cyclerion Therapeutics | Cyclerion Therapeutics, Inc | Cyclerion Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

cy6463 (2 trials)

iw-6463 (3 trials)

Drugs in Phase 1 Trials (3)

itraconazole (sporanox) (1 trial)

Olinciguat (2 trials)

praliciguat (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

MELAS Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5